Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:EEXNYSE:ETWONASDAQ:MXCTNASDAQ:NUTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEEXEmerald$4.62-0.1%$4.08$3.22▼$6.74$917.73M1.05193,888 shs28,059 shsETWOE2open Parent$3.21+0.2%$2.30$1.75▼$4.82$1.10B1.042.82 million shs21.95 million shsMXCTMaxCyte$2.33+0.6%$2.54$2.10▼$5.26$247.19M1.38594,982 shs352,640 shsNUTXNutex Health$166.71+0.8%$122.20$4.16▼$184.28$927.88M-0.169,187 shs32,421 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEEXEmerald-0.22%+3.36%+15.68%+12.58%-17.97%ETWOE2open Parent-0.16%+21.17%+52.62%+39.65%-31.44%MXCTMaxCyte+1.76%+2.67%-20.62%-30.84%-50.64%NUTXNutex Health-0.05%+2.20%+57.83%+201.31%+2,297.74%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEEXEmerald1.4353 of 5 stars3.52.00.80.01.30.00.0ETWOE2open Parent1.5956 of 5 stars0.95.00.00.01.90.82.5MXCTMaxCyte2.5734 of 5 stars3.52.00.00.02.72.50.6NUTXNutex Health2.4484 of 5 stars3.52.00.00.02.63.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEEXEmerald 3.00Buy$7.9071.18% UpsideETWOE2open Parent 1.75Reduce$2.78-13.42% DownsideMXCTMaxCyte 3.00Buy$7.50222.58% UpsideNUTXNutex Health 3.00Buy$262.5057.46% UpsideCurrent Analyst Ratings BreakdownLatest MXCT, EEX, NUTX, and ETWO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025ETWOE2open ParentMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$2.10 ➝ $3.305/20/2025NUTXNutex HealthMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$100.00 ➝ $225.005/15/2025NUTXNutex HealthBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$150.00 ➝ $300.005/2/2025EEXEmeraldRosenblatt SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.80 ➝ $7.804/30/2025ETWOE2open ParentUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$3.00 ➝ $2.504/16/2025ETWOE2open ParentMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$3.00 ➝ $2.304/8/2025NUTXNutex HealthMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$75.00 ➝ $100.003/28/2025ETWOE2open ParentThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$2.60 ➝ $2.303/13/2025EEXEmeraldRosenblatt SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.80 ➝ $7.803/12/2025MXCTMaxCyteBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$6.003/12/2025MXCTMaxCyteStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $9.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEEXEmerald$413.10M2.22$0.68 per share6.83($1.47) per share-3.14ETWOE2open Parent$607.69M1.81$5.43 per share0.59$4.65 per share0.69MXCTMaxCyte$37.68M6.56N/AN/A$2.23 per share1.04NUTXNutex Health$624.28M1.49N/AN/A$17.68 per share9.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEEXEmerald-$8.20M$0.03N/A∞N/A-5.29%-13.26%-1.92%8/5/2025 (Estimated)ETWOE2open Parent-$1.07B-$2.14N/A14.571.05-74.63%4.38%2.12%7/9/2025 (Estimated)MXCTMaxCyte-$37.92M-$0.40N/AN/AN/A-78.36%-16.00%-13.93%8/5/2025 (Estimated)NUTXNutex Health-$45.79M$11.89N/A∞N/A-14.09%-51.27%-9.89%8/6/2025 (Estimated)Latest MXCT, EEX, NUTX, and ETWO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025NUTXNutex Health-$0.15$2.56+$2.71$2.56$81.09 million$211.79 million5/7/2025Q1 2025MXCTMaxCyte-$0.10-$0.10N/A-$0.10$9.05 million$10.39 million5/1/2025Q1 2025EEXEmerald$0.07$0.08+$0.01$0.08$134.30 million$147.70 million4/29/2025Q4 2025ETWOE2open Parent$0.05$0.06+$0.01-$0.79$153.01 million$153.50 million3/31/2025Q4 2024NUTXNutex Health-$0.09$11.12+$11.21$11.12$81.13 million$81.30 million3/14/2025Q4 2024EEXEmerald$0.03$0.03N/A$0.03$108.05 million$106.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEEXEmerald$0.061.30%N/A200.00%N/AETWOE2open ParentN/AN/AN/AN/AN/AMXCTMaxCyteN/AN/AN/AN/AN/ANUTXNutex HealthN/AN/AN/AN/AN/ALatest MXCT, EEX, NUTX, and ETWO DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025EEXEmeraldquarterly$0.01501.3%5/12/20255/12/20255/22/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEEXEmerald1.021.271.27ETWOE2open Parent0.911.081.08MXCTMaxCyteN/A9.819.22NUTXNutex Health3.361.771.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEEXEmerald14.90%ETWOE2open ParentN/AMXCTMaxCyte68.81%NUTXNutex Health5.32%Insider OwnershipCompanyInsider OwnershipEEXEmerald4.00%ETWOE2open Parent4.70%MXCTMaxCyte3.00%NUTXNutex Health38.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEEXEmerald600198.86 million179.64 millionOptionableETWOE2open Parent3,680343.99 million327.11 millionOptionableMXCTMaxCyte80106.32 million102.67 millionOptionableNUTXNutex Health1,1505.57 million3.34 millionNot OptionableMXCT, EEX, NUTX, and ETWO HeadlinesRecent News About These CompaniesNutex Health Inc.: High-Growth Healthcare Innovator With Strong MomentumMay 29 at 6:26 PM | seekingalpha.comNutex Health Inc.: High-Growth Healthcare Innovator With Strong MomentumMay 29 at 6:03 PM | seekingalpha.comNutex Health appoints Grant Thornton as new auditorMay 23, 2025 | uk.investing.comOMERS ADMINISTRATION Corp Buys Shares of 7,300 Nutex Health Inc. (NASDAQ:NUTX)May 23, 2025 | marketbeat.comNUTEX HEALTH ANNOUNCES THE APPOINTMENT OF GRANT THORNTON LLP AS ITS INDEPENDENT AUDITORMay 22, 2025 | prnewswire.comNutex Health (NASDAQ:NUTX) Hits New 52-Week High - Here's WhyMay 22, 2025 | marketbeat.comMaxim Group Raises Nutex Health (NASDAQ:NUTX) Price Target to $225.00May 22, 2025 | americanbankingnews.comHouston's Nutex plans first San Antonio hospital, eyes potential further expansionMay 20, 2025 | bizjournals.comShuttered health center finds new life in first 'micro' hospital in San AntonioMay 20, 2025 | msn.comScissortail Wealth Management LLC Has $308,000 Position in Nutex Health Inc. (NASDAQ:NUTX)May 19, 2025 | marketbeat.comNutex Health: The Stock Has Gotten Ahead Of Itself As Arbitration Revenue NormalizesMay 16, 2025 | seekingalpha.comNutex Health, Inc. (NASDAQ:NUTX) Q1 2025 Earnings Call TranscriptMay 16, 2025 | msn.comNutex Health Inc (NUTX) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Expansion ...May 16, 2025 | finance.yahoo.comNutex Health Inc. (NUTX) Q1 2025 Earnings Conference Call TranscriptMay 14, 2025 | seekingalpha.comNutex Health Shares Rise After 1Q Revenue TriplesMay 14, 2025 | marketwatch.comNUTEX HEALTH REPORTS FIRST QUARTER 2025 FINANCIAL RESULTSMay 13, 2025 | prnewswire.comEarnings Preview For Nutex HealthMay 12, 2025 | benzinga.comRenaissance Technologies LLC Has $244,000 Holdings in Nutex Health Inc. (NASDAQ:NUTX)May 8, 2025 | marketbeat.comNutex Health (NASDAQ:NUTX) Shares Up 8.2% - Here's WhyMay 7, 2025 | marketbeat.comNutex Health Schedules 2025 First Quarter Financial Results Release and Conference CallMay 7, 2025 | prnewswire.comAncora Advisors LLC Makes New $1.33 Million Investment in Nutex Health Inc. (NASDAQ:NUTX)May 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMXCT, EEX, NUTX, and ETWO Company DescriptionsEmerald NYSE:EEX$4.62 -0.01 (-0.11%) As of 03:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Emerald Holding, Inc. operates business-to-business (B2B) trade shows in the United States. The company provides B2B trade show franchises; and B2B print publications and digital media products, which provide industry specific business news and information across various sectors. It also offers B2B e-commerce and digital merchandising solutions to manufacturers and retailers through Elastic Suite and Bulletin platforms. The company serves retail, design, technology, equipment, and safety and security. Emerald Holding, Inc. was incorporated in 2013 and is headquartered in New York, New York.E2open Parent NYSE:ETWO$3.20 +0.01 (+0.16%) As of 03:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.E2open Parent Holdings, Inc. provides cloud-based and end-to-end supply chain management and orchestration SaaS platform in the Americas, Europe, and the Asia Pacific. Its SaaS platform includes various key strategic and operational areas, including omni-channel, demand sensing, supply planning, global trade management, transportation and logistics and manufacturing and supply management. The company's software combines networks, data, and applications to provide a deeply embedded and mission-critical platform that allows its clients to optimize their channel and supply chains. It serves consumer goods, food and beverage, manufacturing, retail, industrial and automotive, aerospace and defense, technology and transportation, and other industries. The company was incorporated in 2020 and is headquartered in Austin, Texas.MaxCyte NASDAQ:MXCT$2.33 +0.02 (+0.65%) As of 03:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.Nutex Health NASDAQ:NUTX$166.70 +1.29 (+0.78%) As of 03:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nutex Health Inc. operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management. The Real Estate segment owns and owns and leases land and hospital building. The Hospital segment develops and operates a network of micro-hospitals, specialty hospitals and hospital outpatient departments which offers 24/7 care. It also provides operational and managerial services, including management, billing, collections, human resources and recruiting, legal, accounting, and marketing. In addition, the company offers healthcare services, including emergency room care, inpatient care, and behavioral health, as well as onsite imaging, such as CT scan, X-ray, MRI, ultrasound, etc.; certified and accredited laboratories; and onsite inpatient pharmacies. The company was founded in 2011 and is based in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Apple Stock Could Rally After Tariffs Are Blocked By Court Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
